Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas

Clinical Neuropharmacology

Volumn 34, Issue 5, 2011, Pages 179-181

  Martinkova, Jana ^a   Trejbalova, Ludmila ^b   Sasikova, Michaela ^b   Benetin, Jan ^b   Valkovic, Peter ^a,c  

^a Physics and Informatics   (Slovakia)

^b SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^c INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE; QUINAGOLIDE; ROPINIROLE; ROTIGOTINE;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPULSIVE EATING; COMPULSIVE SHOPPING; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; FEMALE; FIBROMYALGIA; HUMAN; HYPERSEXUALITY; HYPOPHYSIS ADENOMA; IMPULSE CONTROL DISORDER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGICAL GAMBLING; PREVALENCE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PSYCHOTHERAPY; RESTLESS LEGS SYNDROME; SHY DRAGER SYNDROME; STRUCTURED INTERVIEW; SUBSTITUTION THERAPY;

ADULT; AMINOQUINOLINES; BROMOCRIPTINE; COMBINED MODALITY THERAPY; COMPULSIVE BEHAVIOR; CROSS-SECTIONAL STUDIES; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HUMANS; IMPULSE CONTROL DISORDERS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PREVALENCE; PROLACTIN; PROLACTINOMA; SLOVAKIA;

EID: 80053052817     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3182281b2f     Document Type: Article

References (20)

1. Potenza MN, Voon V, Weintraub D. Drug insight: impulse control disorders and dopamine therapies in Parkinson's disease. Nat Clin Pract Neurol 2007;3:664-672. (Pubitemid 350238058)
2. Lim SY, Evans AH, Miyasaki JM. Impulse control and related disorders in Parkinson's disease: review. Ann N Y Acad Sci 2008;1142:85-107.
3. Giladi N, Weitzman N, Schreiber S, et al. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol 2007;21:501-506. (Pubitemid 47106924)
4. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010;67:589-595.
5. Cornelius JR, Tippmann-Peikert M, Slocumb NL, et al. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 2010;33:81-87.
6. McKeon A, Josephs KA, Klos KJ, et al. Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2007;13:516-519. (Pubitemid 350102309)
7. Quickfall J, Suchowersky O. Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism Relat Disord 2007;13:535-536. (Pubitemid 350110554)
8. Kim YY, Park HY, Kim JM, et al. Pathological hypersexuality induced by dopamine replacement therapy in a patient with progressive supranuclear palsy. J Neuropsychiatry Clin Neurosci 2008;20:496-497.
9. Klos KJ, Bower JH, Josephs KA, et al. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005;11:381-386. (Pubitemid 41317806)
10. Holman AJ. Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. J Gambl Stud 2009;25:425-431.
11. Davie M. Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. J Neuropsychiatry Clin Neurosci 2007;19:473-474. (Pubitemid 350156112)
12. Falhammar H, -arker JY. Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med J Aust 2009;190:97.
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed (Text Revision). Washington, DC: American Psychiatric Association; 2000.
14. Giladi N, Weitzman N, Schreiber S, et al. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol 2007;21:501-506. (Pubitemid 47106924)
15. Gallagher DA, O'Sullivan SS, Evans AH, et al. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 2007;22:1757-1763. (Pubitemid 47597599)
16. Kanovsky P, Bares M, Pohanka M, et al. Penile erections and hypersexuality induced by pergolide treatment in advanced,fluctuating Parkinson's disease. J Neurol 2002;249:112-114. (Pubitemid 34119032)
17. Jimenez-Jimenez FJ, Sayed Y, Garcia-Soldevilla MA, et al. Possible zoophilia associated with dopaminergic therapy in Parkinson disease. Ann Pharmacother 2002;36:1178-1179. (Pubitemid 34755795)
18. Vogel HP, Schiffter R. HypersexualityVa complication of dopaminergic therapy in Parkinson's disease. Pharmacopsychiatria 1983;16:107-110. (Pubitemid 13002434)
19. Wingo TS, Evatt M, Scott B, et al. Impulse control disorders arising in 3 patients treated with rotigotine. Clin Neuropharmacol 2009;32:59-62.
20. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006;21:524-529.